(15) Siehler, S., Wang, Y., Fan, X., Windh, R.T., and Manning, D.R.
Sphingosine 1-phosphate activates nuclear factor-kB through Edg receptors: activation through Edg-3 and Edg-5, but not Edg-1, in human embryonic kidney 293 cells.
J. Biol. Chem., submitted

(3) Siehler, S., Seuwen, K., and Hoyer, D.
[¹²⁵I][Tyr³]octreotide labels human sst₂ and sst₅ receptors.
Europ. J. Pharmacol. 348: 311-320, 1998

(4) Siehler, S., Seuwen, K., and Hoyer, D.
[¹²⁵I]Tyr¹⁰-cortistatin₁₄ labels all five somatostatin receptors.
Naunyn-Schmiedeberg`s Arch. Pharmacol. 357: 483-489, 1998 (PDF file)

(5) Siehler, S., Zupanc, G.K.H., Seuwen, K., and Hoyer, D.
Characterisation of the fish sst₃ receptor, a member of the SRIF₁ receptor family: atypical pharmacological features.
Neuropharmacol. 38: 449-462, 1999

(6) Zupanc*, G.K.H., Siehler*, S., Jones, E.M.C., Seuwen, K., Furuta, H., Hoyer, D., Yano, H.
(* equal contribution)
Molecular cloning and pharmacological characterisation of a somatostatin receptor subtype in the gymnotiform fish Apteronotus albifrons.
Gen. Comp. Endocrinol. 115: 333-345, 1999

(7) Criado, J.R., Li, H., Jiang, X., Spina, M., Huitron-Resendiz, S., Liapakis, G., Calbet, M., Siehler, S., Henriksen, S.J., Koob, G., Hoyer, D., Sutcliffe, J.G., Goodman, M., de Lecea, L.
Structural and compositional determinants of cortistatin activity.
J. Neuroscience Res. 56: 611-619, 1999

(8) Siehler, S., Seuwen, K., and Hoyer, D.
Characterisation of human recombinant somatostatin receptors: 1) radioligand binding studies.
Naunyn-Schmiedeberg`s Arch. Pharmacol. 360: 488-499, 1999 (HTML file)

(9) Siehler, S., and Hoyer, D.
Characterisation of human recombinant somatostatin receptors: 2) modulation of GTPgS binding.
Naunyn-Schmiedeberg`s Arch. Pharmacol. 360: 500-509, 1999 (HTML file)

(10) Siehler, S., and Hoyer, D.
Characterisation of human recombinant somatostatin receptors: 3) modulation of adenylate cyclase activity.
Naunyn-Schmiedeberg`s Arch. Pharmacol. 360: 510-521, 1999 (HTML file)

(11) Siehler, S., and Hoyer, D.
Characterisation of human recombinant somatostatin receptors: 4) modulation of phospholipase C activity.
Naunyn-Schmiedeberg`s Arch. Pharmacol. 360: 522-532, 1999 (HTML file)

(12) Feuerbach, D., Fehlmann, D., Nunn, C., Siehler, S., Langenegger, D., Bouhelal, R., Seuwen, K., and Hoyer, D.
Cloning, expression, and pharmacological characterisation of the mouse somatostatin sst₅ receptor. Neuropharmacology 39: 1451-1462, 2000

(13) Fehlmann, D., Langenegger, D., Schuepbach, E., Siehler, S., Feuerbach, D., and Hoyer, D.
Distribution and characterisation of somatostatin receptor mRNA and binding sites in the brain and periphery.
J. Physiology (Paris) 94: 265-281, 2000 (HTML Abstract)

(14) Siehler, S., Ling, A., Hannon, J., Bouhelal, R., Zupanc, G.K.H., and Hoyer, D.
Fish somatostatin sst₃ receptor: comparison of radioligand and GTPgS binding, adenylate cyclase and phospholipase C activities reveals agonist-dependent pharmacological differences.
Naunyn-Schmiedeberg`s Arch. Pharmacol., submitted

(1) Lampen, A., Siehler, S., Ellerbeck, U., Göttlicher, M., and Nau, H.
New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: activation of the peroxisomal proliferator-activated receptor (PPARd).
Toxicol. Appl. Pharmacol. 160: 238-249, 1999 (PDF file)

(2) Wehrling*, U., Siehler*, S., Ellerbeck, U., Nau, H., and Göttlicher, M.
(* equal contribution)
Induction of differentiation in F9 cells and activation of PPARd by valproic acid and its teratogenic derivatives.
Mol. Pharmacol., 59: in press (May), 2001